Drug intelligence / Profile preview

celecoxib + gemcitabine

Development stage: Unknown
Lead developer: Ferring Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This drug represents a **combination therapy** of **celecoxib**, a selective cyclooxygenase-2 (COX-2) inhibitor, and **gemcitabine**, a nucleoside analog used as chemotherapy. Celecoxib reduces the production of prostaglandin E2 and inflammation, while gemcitabine inhibits DNA synthesis, resulting in cell death, particularly in rapidly dividing tumor cells. This combination has been studied primarily in advanced pancreatic cancer and other solid tumors to assess additive or synergistic antitumor effects, including modulation of immune response by enabling immunogenic cell death.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on celecoxib + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on celecoxib + gemcitabine.

Explore the full profile